These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 21961647)

  • 1. Kinetic, mechanistic, and structural modeling studies of truncated wild-type leucine-rich repeat kinase 2 and the G2019S mutant.
    Liu M; Kang S; Ray S; Jackson J; Zaitsev AD; Gerber SA; Cuny GD; Glicksman MA
    Biochemistry; 2011 Nov; 50(43):9399-408. PubMed ID: 21961647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities.
    Liu M; Dobson B; Glicksman MA; Yue Z; Stein RL
    Biochemistry; 2010 Mar; 49(9):2008-17. PubMed ID: 20146535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.
    Li X; Tan YC; Poulose S; Olanow CW; Huang XY; Yue Z
    J Neurochem; 2007 Oct; 103(1):238-47. PubMed ID: 17623048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The R1441C mutation of LRRK2 disrupts GTP hydrolysis.
    Lewis PA; Greggio E; Beilina A; Jain S; Baker A; Cookson MR
    Biochem Biophys Res Commun; 2007 Jun; 357(3):668-71. PubMed ID: 17442267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Parkinson disease-linked LRRK2 protein mutation I2020T stabilizes an active state conformation leading to increased kinase activity.
    Ray S; Bender S; Kang S; Lin R; Glicksman MA; Liu M
    J Biol Chem; 2014 May; 289(19):13042-53. PubMed ID: 24695735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's disease-associated LRRK2.
    Biosa A; Trancikova A; Civiero L; Glauser L; Bubacco L; Greggio E; Moore DJ
    Hum Mol Genet; 2013 Mar; 22(6):1140-56. PubMed ID: 23241358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation.
    Rudenko IN; Kaganovich A; Hauser DN; Beylina A; Chia R; Ding J; Maric D; Jaffe H; Cookson MR
    Biochem J; 2012 Aug; 446(1):99-111. PubMed ID: 22612223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dual enzyme LRRK2 hydrolyzes GTP in both its GTPase and kinase domains in vitro.
    Liu Z; West AB
    Biochim Biophys Acta Proteins Proteom; 2017 Mar; 1865(3):274-280. PubMed ID: 27939437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S.
    Liu M; Bender SA; Cuny GD; Sherman W; Glicksman M; Ray SS
    Biochemistry; 2013 Mar; 52(10):1725-36. PubMed ID: 23379419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation.
    Luzón-Toro B; Rubio de la Torre E; Delgado A; Pérez-Tur J; Hilfiker S
    Hum Mol Genet; 2007 Sep; 16(17):2031-9. PubMed ID: 17584768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity.
    Guo L; Gandhi PN; Wang W; Petersen RB; Wilson-Delfosse AL; Chen SG
    Exp Cell Res; 2007 Oct; 313(16):3658-70. PubMed ID: 17706965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unique functional and structural properties of the LRRK2 protein ATP-binding pocket.
    Liu Z; Galemmo RA; Fraser KB; Moehle MS; Sen S; Volpicelli-Daley LA; DeLucas LJ; Ross LJ; Valiyaveettil J; Moukha-Chafiq O; Pathak AK; Ananthan S; Kezar H; White EL; Gupta V; Maddry JA; Suto MJ; West AB
    J Biol Chem; 2014 Nov; 289(47):32937-51. PubMed ID: 25228699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of divalent manganese and magnesium on the kinase activity of leucine-rich repeat kinase 2 (LRRK2).
    Lovitt B; Vanderporten EC; Sheng Z; Zhu H; Drummond J; Liu Y
    Biochemistry; 2010 Apr; 49(14):3092-100. PubMed ID: 20205471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization.
    Sen S; Webber PJ; West AB
    J Biol Chem; 2009 Dec; 284(52):36346-36356. PubMed ID: 19826009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LRRK2 Facilitates tau Phosphorylation through Strong Interaction with tau and cdk5.
    Shanley MR; Hawley D; Leung S; Zaidi NF; Dave R; Schlosser KA; Bandopadhyay R; Gerber SA; Liu M
    Biochemistry; 2015 Aug; 54(33):5198-208. PubMed ID: 26268594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1.
    Stafa K; Trancikova A; Webber PJ; Glauser L; West AB; Moore DJ
    PLoS Genet; 2012; 8(2):e1002526. PubMed ID: 22363216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The G2019S pathogenic mutation disrupts sensitivity of leucine-rich repeat kinase 2 to manganese kinase inhibition.
    Covy JP; Giasson BI
    J Neurochem; 2010 Oct; 115(1):36-46. PubMed ID: 20626563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leucine-rich repeat kinase 2 mutants I2020T and G2019S exhibit altered kinase inhibitor sensitivity.
    Reichling LJ; Riddle SM
    Biochem Biophys Res Commun; 2009 Jun; 384(2):255-8. PubMed ID: 19397894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinase activity of mutant LRRK2 manifests differently in hetero-dimeric vs. homo-dimeric complexes.
    Leandrou E; Markidi E; Memou A; Melachroinou K; Greggio E; Rideout HJ
    Biochem J; 2019 Feb; 476(3):559-579. PubMed ID: 30670570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and characterization of a leucine-rich repeat kinase 2 (LRRK2) consensus phosphorylation motif.
    Pungaliya PP; Bai Y; Lipinski K; Anand VS; Sen S; Brown EL; Bates B; Reinhart PH; West AB; Hirst WD; Braithwaite SP
    PLoS One; 2010 Oct; 5(10):e13672. PubMed ID: 21060682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.